Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Emanuele Focà, Manuela Colafigli et al.|Journal of Antimicrobial Chemotherapy|2016Cited by 75
Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patientsGianmaria Baldin, Simona Di Giambenedetto, Arturo Ciccullo et al.|International Journal of Antimicrobial Agents|2019Cited by 55
Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical TrialStefano Rusconi, Giulia Marchetti, Paola Vitiello et al.|PLoS ONE|2013Cited by 42
A Comparison between two Dolutegravir-Based two-drug Regimens as Switch Strategies in a Multicentre Cohort of HIV-1-Infected PatientsArturo Ciccullo, Simona Di Giambenedetto, Gianmaria Baldin et al.|Antiviral Therapy|2018Cited by 37
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trialMassimiliano Fabbiani, Roberta Gagliardini, Nicoletta Ciccarelli et al.|Journal of Antimicrobial Chemotherapy|2018Cited by 33